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Hidradenitis suppurativa is one of the most distressing dermatological conditions and has
a significant negative impact on patients’ quality of life. However, the exact pathogenic
mechanisms remain incompletely understood and—therefore—efficient therapies are still
lacking. The current manuscript focuses on new findings on its pathogenic mechanisms
and aims to provide practical therapy recommendations.
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INTRODUCTION
Hidradenitis suppurativa (HS) is a chronic skin disorder, which profoundly decrease quality of life
because of emotional, physical and psychologic consequences (1–6). This recurrent inflammatory
skin condition with an estimated prevalence of 1–4% is more frequent in women (2, 5, 7, 8).
Most frequently, the age of onset is between 20 and 40 years of life, although postmenopausal
women and prepubertal children with new-onset HS have been reported (2, 5, 9, 10). The clinical
manifestations range from inflamed nodules and abscesses to draining sinus tracts and formation of
scars (5, 11, 12). The pain, drainage, malodor, and disfigurement associated with HS all contribute
to the remarkable psychosocial impact of the disease with negative effects on the patients’ quality
of life that cannot be overestimated (5, 11, 12). In fact, HS is associated with an increased risk of
completed suicide, an increased risk of adverse cardiovascular outcomes and increased all-cause
mortality independent of measured confounders (13, 14). Unfortunately, the exact pathogenesis of
HS remains unclear. Despite the existence of multiple therapeutic approaches and combinational
treatments, effective management of moderate to severe HS remains elusive in many cases. In this
manuscript, we summarize the current knowledge about pathophysiology and treatment of HS.
PATHOGENESIS
Mechanism
The precise pathogenesis of HS remains still unclear. This chronic skin disorder might be caused by
genetic, endocrine, environmental, and microbiological factors (15). The primary event in disease
development is thought to be follicular occlusion, based on histopathological observations in very
early lesions (16, 17). Follicular occlusion is likely due to infundibular keratosis and hyperplasia
of the follicular epithelium, which leads to accumulation of cellular debris and formation of cysts
(16, 18–20). The hair follicle eventually ruptures, followed by release of follicular contents to the
dermis, which induces a significant expression of inflammatory mediators and recruitment of
inflammatory cells. The end results are abscess formation, painful inflammation and sinus tract
formation and scarring, in later stages (16, 18–20).
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Genetics
Two main observations point to a genetic background of HS.
First, approximately one third of HS patients have at least
one family member also suffering from HS, suggesting an
inheritable genetic predisposition (21). Second, families with
several mutations or changes in genes of the gamma-secretase
family (including nicastrin (NCSTN), presenilin 1 (PSEN1),
presenilin enhancer 2 (PSENEN) gene mutation) show an
autosomal dominant inheritance of HS, indicating a pathogenic
role of these genes in HS (22–26). The resulting alteration in γ-
secretase function might result in HS by affecting downstream
Notch signaling in the skin (23).
However, these patients show a severe disease phenotype not
entirely typical of “sporadic” HS, raising questions as to what
degree this genetic background is representative for all cases
of HS. Nevertheless, taken together current evidence strongly
supports a genetic predisposition for HS development.
Inflammatory Pathways in Hidradenitis
Suppurativa
The excessive inflammatory response seen in lesional skin of
HS is thought to be triggered by a combination of genetic,
anatomical, immunological, and environmental factors (27, 28).
Increased activity of dendritic cells and T cells cause keratinocyte
hyperplasia via the actions of IL-23 and IL-12 and a Th17
immune response (27–30). As HS progresses, increased levels of
interleukin (IL)-1, tumor necrosis factor (TNF), IL-17, caspase-
1, S100A8, S100A9, and IL-10 appear in the tissue together with
a recruitment of neutrophils, mast cells and monocytes (16, 27,
28, 31–34). Recent evidence further points to autoinflammatory
mechanism in HS. HS skin shows increased formation of
neutrophil extracellular traps (NET). Intriguingly, immune
responses to neutrophil and NET-related antigens have been
linked to enhanced immune dysregulation and inflammation
(35). In combination with the strong type I IFN signature in
HS skin, these findings suggest a key involvement of the innate
immune response in the pathogenesis of HS (36). As healing from
the remarkable inflamation progresses, tunneling and scarring of
the tissue occur (27, 28, 31). The development of sinus tracts and
scarring is associated with matrix metalloproteinase-2 (MMP-
2), transforming growth factor beta (TGF-ß) and (Intercellular
adhesion molecule-1 (ICAM-1), with possible augmentation of
TGF-ß and ICAM-1 signaling via specific components of the
microbiome (27, 28).
Bacteria
Bacterial involvement inHS pathogenesis remains highly debated
(37, 38). A number of studies have shown that cultures of HS
lesions are predominately sterile or contain only commensal skin
flora (38, 39). As a result, primary infection is viewed as an
unlikely cause of HS (38, 39). In addition, the lack of strong
therapeutic effect of antibiotic treatment further argues against
a primary infectious cause (40). However, it is still possible
that microbial “dysbiosis” and an altered skin microbiome are
important factors contributing to HS pathogenesis. In fact,
the cutaneous microbiome in patients with HS is substantially
different from that of normal donors. A variety of partly
overrepresented, partly unique species have been isolated from
HS lesions and linked to various features of the disease
(41, 42). Yet, their pathogenetic contribution has remained
elusive, in large part because of the technical and experimental
difficulties of investigating their causal role in humans (38,
42). Furthermore, the microanatomical intricacies of HS skin
with its fistulas and sinus tracts represent an important basis
for biofilm formation, bacterial colonization, and secondary
infection, which contribute to disease exacerbations, suppuration
and extension of lesions (38, 43). Although the role of bacterial
biofilm in HS is highly debated, the association between biofilm
and the number of regulatory T cells (TREG) in a recent
study supports the concept of dysbiosis as a factor in the
preclinical HS lesions (44). In summary, microbial colonization
and infection are likely pathogenic contributors to HS, but it
is still unclear if the colonization of bacteria is a primary or
secondary event in the evolution of HS (37). Since the follicular
infundibulum is populated by a broad microbiome, deficiencies
in the follicular skin immune system might cause microbial
overgrowth. However, another theories suggest that an overactive
immune system might contribute to a remarkable inflammatory
response to harmless, normal flora (16).
Other Associated Factors
Mechanical stress (45), metabolic syndrome (2, 37, 38), diet
(46), smoking (2, 38), and hormonal factors (47) have been
reported in previous studies to contribute to the development
or exacerbation of HS. While the epidemiological evidence for
this is undisputed, at least for some factors such as smoking and
obesity, the mechanism by which these factors contribute to HS
pathogenesis remain far from clear. Smoking, for instance, is
one of the best-documented behavioral risk factors for HS, but
the mechanisms by which it triggers HS is poorly understood.
There are thousands of chemicals in tobacco smoke, which have
the potential to activate keratinocytes, fibroblasts, and immune
cells. Mechanistically, these substances may trigger skin cells via
two types of receptors: aryl hydrocarbon receptors and nicotinic
acetylcholine receptors (16, 48, 49). In keratinocytes, activation
of these receptors can lead to infundibular epithelial hyperplasia,
acanthosis and excessive cornification (16, 49). Furthermore,
tobacco smoke can induce expression of proinflammatory
cytokines such as TNF-a, IL-8, IL-1 α, and IL-1β leading to
neutrophil chemotaxis, altered function of TREG, as well as
activation of Th17 pathways (16, 27, 50–53). Other important
risk factors for HS, obesity and diabetes, can also result in
overproduction of TNF-α, IL-1β, and IL-6 through activated
macrophages in adipose tissue (27, 51–53). In addition, obesity
can worsen HS through increased skin-clothing and skin-skin
friction, as mechanical stress can increase follicular occlusion and
rupture (16, 45).
Hormones are also thought to be involved in HS pathogenesis.
This is primarily based on a number of clinical observations and
promising effects of antiandrogen treatments. For instance, some
female HS patients observe worsening of disease in conjunction
with menstruation or after starting hormonal contraception
with androgen effects (e.g., progesterone-containing drugs)
(47, 54). Hormones can induce occlusion and plugging of
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the follicle and increase production and composition of
sebum, thereby contributing to the vicious cycle of HS skin
inflammation (55, 56).
Suggested Therapy Approach Based on
the Current Knowledge
There is no single efficient therapy for the skin disorder.
As a result, clinicians typically should choose from different
treatment modalities and often have to combine them to
achieve disease control. The choice of treatment depends on
the distribution and overall severity of disease, the anatomic
location and inflammatory activity of the lesions, the patient’s
comorbidities, as well as treatment cost and availability (2,
5, 9, 38). In order to assess the severity and extent of
hidradenitis suppurativa various scoring systems are in common
use: hurley stages, sartorius hidradenitis suppurativa score,
hidradenitis suppurativa physician global assessment (HS-PGA)
and hidradenitis suppurativa clinical response (HiSCR) (57–59).
HS management is often complex. The standard of
care management requires an individualized approach in
a multifaceted approach, ranging from self-management
(e.g., avoidance of skin trauma, pain management, smoking
cessation, weight loss and hygiene practices) to local therapies,
systemic antibiotics, and a wide range of immunomodulating
agents, as well as surgical interventions such as excisional and
laser surgeries (6, 15, 38, 39, 60). Additionally, the diagnosis
and management of medical comorbidities and referral to
psychiatrist might be taken into consideration (61). An overview
of a suggested multidimensional approach is summarized
in Figure 1.
Life Style Modification
Because smoking and obesity have the greatest association with
the severity of the disease, it is recommended that patients with
HS stop smoking and reduce their body weight. In addition,
loose-fitting clothing in order is advised to avoid friction and
FIGURE 1 | Clinical practice recommendations for the treatment of HS, modified from Hunger et al. and Saunte and Jemec (15, 31).
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mechanical stress (2, 6, 15). Zinc might be suggested for patients
with Hurley stage I-II, as an innate immunity modulator (6, 62).
Pain Management
Acute and chronic pain is a remarkable contributor to quality
of life in individuals with HS, and reduction of inflammation
can improve the pain (6, 63). Depression, which plays a
crucial role in the perception of pain, is a risk factor for
the development of chronic pain in these patients (6, 17, 63).
Managing HS pain is complicated. Therefore, a multidisciplinary
approach, including pain assessment, pain scoring, and the
involvement of a pain specialist, is warranted (6, 17). A variety
of alternatives are reported in the recent studies, such as
local analgesics, non-steroidal paracetamol, anti-inflammatory
drugs, pregabalin, gabapentin, venlafaxine, and duloxetine (17).
In more complex cases may require the judicious use of
antidepressants (64). In selected patients with severe pain, careful
administration of individualized, short-acting opioid analgesics
might be necessary (6, 17).
Local Therapy and Wound Care
Local treatment of this chronic disorder includes antiseptic
washes, keratolytic agents and topical antibiotics (6, 60). Selection
of dressing is based on the location, skin condition, amount
of drainage, cost and patient preference (6, 60). For local
treatment of selected large open wounds, use of negative-pressure
therapy for a short period of time (1–4 weeks) followed by
delayed reconstruction might be effective (6). Clinical experience
supported the use of Intralesional corticosteroid injection (e.g.,
triamcinolone 3–5mg) only for short-term control of acute and
recalcitrant HS lesions (60, 65). Pain is typically reduced fast
and a reduction in edema, erythema, suppuration and lesion size
occur after a few days. However, the long-term efficacy of this
approach remains unclear and local side effects, most notably
skin atrophy, have to be carefully monitored (31, 65).
Antibiotics
Available evidence-based literature on the administration of
antibiotics in this disorder is limited and mostly restricted
to retrospective studies (66). Determining the frequency and
duration of antibiotic use should balance of antibiotic use vs.
potential harms associated with antibiotic resistance, because
findings of recent studies stated that antibiotic therapy for
HS treatment might be inducing antibiotic resistance (67).
Typically, HS recurs following cessation of antibiotic therapy,
making repeated or long-term treatments necessary, with all
their potential harmful side effects (60). For Hurley stage I-
II, especially in the absence of abscesses, topical clindamycin
1% is a possible therapy (60, 66, 68, 69). However, it carries
a high risk of bacterial resistance (60, 66, 68, 69). If there are
frequent exacerbations and/or several lesions the administration
of systemic antibiotics can be recommended (66, 69). For
example, tetracyclines (e.g., doxycycline 50–100 twice daily) are
considered in mild-to-moderate HS for a 12-weeks course or
as a long-term maintenance alternative, when appropriate (60).
For the patients with Hurley stage II-III systemic clindamycin
and rifampicin (300mg twice daily) could be suggested as a
second-line therapy for mild-to-moderate HS or as a first-line
or adjunct therapy in the patients with severe disease (60, 66,
70, 71). A triple regimen of moxifloxacin (400mg once daily),
rifampicin (10 mg/kg once daily) and metronidazole (500mg
thrice daily) administered for up to 12 weeks, with metronidazole
discontinuation after 6 weeks, might be considered as second-
or third-line alternative therapy in moderate-to-severe disease
(60, 66). Dapsone might be recommended as an effective and
safe alternative therapeutic option for a minority of patients as
long-term maintenance therapy (60, 72, 73). The effect could
be due to either its anti-inflammatory or antibacterial effects,
or both. However, rapid recurrence after stopping the therapy
suggests that its anti-inflammatory effects are possible more
prominent (60, 72).
Other Systemic Therapies
A short-term systemic corticosteroid therapy could be
recommended for acute conditions or to bridge to other
treatments (60). However, long-term systemic steroid therapy
tapered to the lowest possible dose might be an alternative
option for the patients with severe disease, as an adjunct
therapy in patients without sufficient response to standard
recommended therapies (60). Hormonal agents, such as
estrogen-containing combined oral contraceptives cyproterone
acetate, spironolactone, metformin, and finasteride, might be
recommended in the female patients, either as monotherapy
for mild-to-moderate disease or in combination with other
treatments for severe HS (60, 74–77). Isotretinoin could be
recommended only as a second- or third-line treatment or in
patients with concomitant acne (60, 78, 79). Cyclosporine might
be considered in cases of moderate-to-severe disease who have
failed or are not suitable for other therapies (60, 80). Recent
studies do not recommend the administration of azathioprine or
methotrexate in the treatment of HS (60, 81, 82).
Administration of Biologics in HS
Immunomodulation is becoming popular formoderate-to-severe
form of the disease. Targeting the tumor necrosis factor (TNF),
interleukin 1 (IL-1), IL-12, and IL-23 has been considered as
potential therapies (60, 83).
Adalimumab is recommended as the first-line biologic
therapy for moderate-to-severe HS (60, 66), followed by
Infliximab and anakinra as second- and third-line options,
respectively (66, 84, 85). The recommended dose of adalimumab
in HS is 160mg on Week 0, 80mg on Week 2 and then
40mg weekly (60, 66). Recent studies suggest that those patients
who do not respond to therapy within 12 weeks (<25%
improvement in inflammatory nodules and abscesses) should
discontinue the drug (66, 86–89). However, the patients with
partial or good should continue the therapy with ongoing
assessment (66, 86–89).
Evidence is lacking for other biologic therapies, and any
clinical decisions should be based on close monitoring and risk:
benefit assessments (66). Recent studies showed administration
of other biologics such as other TNF-alpha blockers (66, 90–
92), ustekinumab, (93–96) secukinumab, (97, 98) bimekizumab,
(99) canakinumab, (3, 100) apremilast, (1, 101) anakinra, (102)
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guselkumab (103, 104), and rituximab (105) in management
of HS.
Most biologics are well-tolerated and show a favorable safety
profile in the short- to medium-term. However, long-term
safety concerns, including infection risks, the development of
malignancy and demyelinating disorders should be to assessed
(19). These issues are remarkable in the treatment of HS, where
the biologics dosing is generally higher in comparison to other
inflammatory skin disorders such as psoriasis. As a result, patient
selection is crucial, because complete response is not the norm
and not all patients tolerate or respond well to these therapies.
Critical monitoring of therapy effects and side effects has to be
carefully done under treatment to inform continuous risk-benefit
assessment. In case of unfavorable outcome of such assessment,
other treatment modalities have to be taken into consideration,
such as surgery (19).
Surgical Modalities
Planning of type of surgery and required margins should be
cleared in cooperation with the patient and based on the
severity of the disease (15, 39, 66). Local excision of single
lesions is only suggested in well-circumscribed, localized cases
of Hurley I-II (15). For painful abscesses, no medical therapy
will be effective (6, 15, 43, 66, 106, 107). Therefore, surgical
drainage might be demanded to relieve pain; however, this
should not be considered as sole treatment, because recurrence
is most of the patients inevitable (6, 15, 43, 66, 106, 107).
Extensive excision, electrosurgical excision (with or without
reconstruction) CO2 laser could be appropriate for chronic
lesions to prevent recurrence (5, 6, 66, 108–111). Wound healing
following surgery may be through primary closure, delayed
primary closure, secondary intention, grafts, flaps, and/or skin
substitutes (5, 6, 66, 108–111). Furthermore, a new surgical
approach was described recently, the step-by-step surgery, which
consists in consecutively removing portions of HS skin with
secondary intention healing (112). Recent studies suggest that
continuing medical therapy in the perioperative period might be
beneficial and reduce risk of postoperative complications (6).
Laser Therapy
Most of laser therapies have been focused of modification of
disease activity in the groin and axillae, because, the destruction
of the pilosebaceous apparatus might prevent the extension
of disease (17). Neodymium-doped yttrium aluminum garnet
(Nd:YAG) laser is applicable for Hurley stage II-III disease (6,
17, 39). Furthermore, CO2 laser excision can be considered in
patients with Hurley stage II-III with fibrotic sinus tracts (6).
CONCLUSIONS
In conclusion, HS is characterized by a pathological reaction
pattern of the follicular epithelium of the apocrine gland-
bearing skin to yet ill-defined insults. As a result, the follicular
epithelium becomes hyperplastic, showing hyperkeratosis of the
infundibulum, follicular occlusion, and cyst formation. Rupture
of such cysts and consecutive invasion of follicular material into
the dermis is likely a key step in triggering a remarkable immune
response, which lies at the heart of painful inflammation and
abscess formation. In later stages, uncontrolled inflammation
leads to sinus tract formation and scarring. There is no uniformly
effective therapy for HS. As a result, clinicians should take a
multifaceted approach depending on the patients’ needs and
on features of the disease. Therapy modalities range from self-
management and topical treatments to systemic antibiotics,
immunomodulating agents, as well as surgical interventions. All
in all, it is recommended to avoid the trigger factors such as:
smoking, obesity, mechanical friction and shaving. Furthermore,
local disinfectants and/or topical antibiotics are suggested in
order avoid bacterial superinfections and reduce inflammation. If
topical agents are not sufficient, systemic antibiotics are typically
given. If antibiotics are not sufficient or no longer effective, other
systemic therapies (e.g., adalimumab, dapsone, systemic steroids,
or cyclosporine)might be used in patients with refractory disease.
Additionally, if needed different surgical interventions might be
taken into consideration in cooperation with the patient and
based on the severity of the disease.
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